Skip to main content

Advertisement

Table 11 Resistance rates in China, U.S. and Kuwait, hospital surveillance data for 2001

From: Antibiotic resistance as a global threat: Evidence from China, Kuwait and the United States

From Tables 1,2,3,8 and 9; Unit: %
Bacterium(a) Antibiotic(s) Pair China U.S. Kuwait
SAU Methicillin A 37 38 9
SPN Erythromycin B 73 19 23
  Cefotaxime C 0 16 4
Enterococcus spp Vancomycin D 4 10 0
ECO Ceftazidime E 9 1* 5
  Cefotaxime F 18 1* 1
  Ceftriaxone G 21 1* 1
  Ciprofloxacin/Ofloxacin H 56 3 26
PAE Ceftazidime I 17 9 27
  Ciprofloxacin/Ofloxacin J 27 28 31
KPN Ceftazidime K 9 4* 14
  Cefotaxime L 17 4* 13
  Ceftriaxone M 20 4* 13
  Ciprofloxacin N 18 12**[27] 18
Salmonella spp Amoxicillin-clavulanate O 10 4 7
  Ceftriaxone P 5 1 0
  Ciprofloxacin Q 0 0.4 10
  TMP/SMX*** R 0 3 0
  Gentamicin S 10 2 0
Shigella spp Amoxicillin-clavulanate T 35 2 20
  Ceftriaxone U 6 0 0
  Ciprofloxacin V 6 0 0
  TMP/SMX W 0 53 0
  Gentamicin X 18 0.2 0
   Average 17 7 9
  1. * The original U.S. NNIS reported resistance rates to either one of the Cef3 drugs, i.e. ceftazidime, cefotaxime or ceftriaxone. We assume the same rates for each drug.
  2. ** Based on surveillance of ICU patients
  3. *** TMP/SMX = Trimethoprim/Sulfamethoxazole